Live Breaking News & Updates on Phase 2 Skylark Trial Nct04430894

Stay updated with breaking news from Phase 2 skylark trial nct04430894 . Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Isa-KRd Produces Deep, Durable Response Rates in Newly Diagnosed, Transplant-Eligible Multiple Myeloma

The addition of isatuximab-irfc to carfilzomib, lenalidomide, and dexamethasone was well tolerated and elicited a 100% objective response rate in standard- and high-risk, transplant-eligible patients with newly diagnosed multiple myeloma. ....

Elizabethk Odonnell , Dana Farber Cancer Institute , Drug Administration , Professor Of Medicine At Harvard Medical School , Early Detection , Assistant Professor , Harvard Medical School , Ash Annual Meeting , Phase 2 Skylark Trial Nct04430894 , Newly Diagnosed Multiple Myeloma Ndmm , Isatuximab Irfc ,